NASDAQ:INDP

Indaptus Therapeutics Stock Forecast, Price & News

$8.84

-1.24 (-12.30 %)

(As of 09/20/2021 03:37 PM ET)

Add

Compare

Today's Range

$8.65

▼

$9.62

50-Day Range N/A

52-Week Range

$6.84

▼

$28.83

Volume16,196 shs

Average Volume7.42 million shs

Market Capitalization$47.79 million

P/E RatioN/A

Dividend YieldN/A

Beta0.85

30 days | 90 days | 365 days | Advanced Chart

Receive INDP News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. The company is headquartered in Jerusalem, Israel.

Pre-market Movers: LPTX, IRNT, AGIL, IO, INDP…
September 16, 2021 | markets.businessinsider.com

Thinking about buying stock in Indaptus Therapeutics, Farmmi, Ironnet, Vinco Ventures, or Aterian?
September 15, 2021 | benzinga.com

Indaptus Therapeutics Receives Notice of Allowance for Strategic Patent
September 15, 2021 | finance.yahoo.com

Head to Head Survey: Indaptus Therapeutics (INDP) versus The Competition
September 6, 2021 | americanbankingnews.com

Indaptus Therapeutics Inc.
August 9, 2021 | barrons.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:INDP
Previous Symbol
CUSIPN/A
CIKN/A
Webintecpharma.com
Phone(722) 586-4657
Employees40
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$16.18 per share
Price / Book0.55

Profitability

EPS (Most Recent Fiscal Year)($16.32)
Net Income$-14,130,000.00
Net MarginsN/A
Return on Equity-131.09%
Return on Assets-92.04%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares5,406,000
Market Cap$47.79 million
Next Earnings Date11/4/2021 (Estimated)
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.13 out of 5 stars

Medical Sector

1314th out of 1,352 stocks

Pharmaceutical Preparations Industry

643rd out of 665 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Indaptus Therapeutics.

0.0 Community Rank

Outperform Votes
Indaptus Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Indaptus Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Indaptus Therapeutics and other stocks. Vote “Outperform” if you believe INDP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INDP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Indaptus Therapeutics does not currently pay a dividend.
Dividend Growth
Indaptus Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Indaptus Therapeutics is held by insiders.
Percentage Held by Institutions
Only 36.95% of the stock of Indaptus Therapeutics is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Indaptus Therapeutics are expected to decrease in the coming year, from $11.96 to ($9.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Indaptus Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Indaptus Therapeutics is -0.56, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Indaptus Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Indaptus Therapeutics (NASDAQ:INDP) Frequently Asked Questions

What stocks does MarketBeat like better than Indaptus Therapeutics?

Wall Street analysts have given Indaptus Therapeutics a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Indaptus Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Indaptus Therapeutics' next earnings date?

Indaptus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Indaptus Therapeutics.

Who are Indaptus Therapeutics' key executives?

Indaptus Therapeutics' management team includes the following people:

Jeffrey A. Meckler, Chief Executive Officer & Director
Nir Sassi, Chief Financial Officer
Michael James Newman, Director & Chief Scientific Officer
Walt A. Linscott, Chief Business Officer

Who are some of Indaptus Therapeutics' key competitors?

Some companies that are related to Indaptus Therapeutics include Sol-Gel Technologies (SLGL), Seelos Therapeutics (SEEL), Galera Therapeutics (GRTX), Kala Pharmaceuticals (KALA), NextCure (NXTC), MediciNova (MNOV), BioVie (BIVI), ObsEva (OBSV), Osmotica Pharmaceuticals (OSMT), Equillium (EQ), Enlivex Therapeutics (ENLV), CorMedix (CRMD), Tyme Technologies (TYME), Entasis Therapeutics (ETTX) and Zynerba Pharmaceuticals (ZYNE).
View all of INDP's competitors.

What is Indaptus Therapeutics' stock symbol?

Indaptus Therapeutics trades on the NASDAQ under the ticker symbol "INDP."

How do I buy shares of Indaptus Therapeutics?

Shares of INDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Indaptus Therapeutics' stock price today?

One share of INDP stock can currently be purchased for approximately $8.98.

How much money does Indaptus Therapeutics make?

Indaptus Therapeutics has a market capitalization of $48.55 million. The company earns $-14,130,000.00 in net income (profit) each year or ($16.32) on an earnings per share basis.

How many employees does Indaptus Therapeutics have?

Indaptus Therapeutics employs 40 workers across the globe.

What is Indaptus Therapeutics' official website?

The official website for Indaptus Therapeutics is intecpharma.com.

Where are Indaptus Therapeutics' headquarters?

Indaptus Therapeutics is headquartered at 12 Hartom Street, Har Hotzvim, Jerusalem 777512.

How can I contact Indaptus Therapeutics?

Indaptus Therapeutics' mailing address is 12 Hartom Street, Har Hotzvim, Jerusalem 777512. The company can be reached via phone at (722) 586-4657 or via email at [email protected].

This page was last updated on 9/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here